<DOC>
	<DOCNO>NCT00751270</DOCNO>
	<brief_summary>This phase I study evaluated Gene Mediated Cytotoxic Immunotherapy approach malignant glioma , include glioblastoma multiforme anaplastic astrocytoma . The purpose study assess safety feasibility deliver experimental approach call GliAtak use AdV-tk , adenoviral vector contain Herpes Simplex thymidine kinase gene , plus oral anti-herpetic prodrug , valacyclovir , combination standard care radiation .</brief_summary>
	<brief_title>Phase 1b Study AdV-tk + Valacyclovir Combined With Radiation Therapy Malignant Gliomas</brief_title>
	<detailed_description>This study design include patient newly diagnose unresectable ( Arm A ) resectable ( Arm B ) malignant glioma . Three dose level AdV-tk evaluate fix dose level valacyclovir prodrug . AdV-tk delivered tumor cell stereotactic injection tumor time biopsy ( Arm A ) injection tumor bed follow resection ( Arm B ) . Oral valacyclovir begin 1-3 day AdV-tk injection continue 14 day . Standard radiation therapy begin 3-7 day follow AdV-tk injection maximize synergy radiation . Standard temozolomide could administer completion valacyclovir .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Presumed malignant glioma base clinical radiologic evaluation ( pathologic confirmation malignant glioma must make time stereotactic biopsy resection prior AdVtk injection ; possible , injection perform subject longer eligible study ) . Tumor must accessible injection must locate brainstem , midbrain , contain within ventricular system , locate infratentorial location . Patients must plan undergo standard radiation therapy . Patients must 18 year age old . Performance status must KPS &gt; equal 70 . Patients must SGOT ( AST ) &lt; 3x upper limit normal . Patients must serum creatinine &lt; 2mg/dl calculate creatinine clearance &gt; 10ml/min . Patients must platelets &gt; 100,000/mm3 WBC &gt; 3000/mm3 . Patients reproductive age must agree use medically accept form birth control study . Patients must give study specific inform consent prior enrollment . Patients must able tolerate MRI scan procedure Prior ongoing liver disease include known cirrhosis , hepatitis B C infection exclude patient distant history resolve hepatitis A infection . Patients immunosuppressive drug ( exception corticosteroid ) Known HIV+ patient . Patients acute infection ( viral , bacterial fungal infection require therapy ) . Pregnant breast feeding patient . Female patient childbearing age must negative serum urine pregnancy test within 1 week begin therapy . Evidence metastatic disease malignancy ( except squamous basal cell skin cancer ) . Prior radiation therapy brain prior treatment brain tumor ( except prior biopsy subtotal resection ) . Other serious comorbid illness compromise organ function . Patients may receive temozolomide valacyclovir complete may receive investigational antitumor agent within 30 day prior study entry active participation study ( define study entry tumor progression ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>Tumor Vaccine</keyword>
	<keyword>Cytotoxicity</keyword>
	<keyword>Radiation</keyword>
</DOC>